PeptideScanner
Investigational↗Metabolic↗

Amycretin↗

An amylin and GLP-1 receptor agonist candidate. This profile cites a completed ClinicalTrials.gov study record.↗

Citation markers ↗ open the public records supporting the adjacent statements.

Profile update · July 27, 2026

We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change. 1

This version supersedes public version 1.

Start here

The evidence at a glance

What is its status in the cited records?

Investigational. ClinicalTrials.gov lists a Novo Nordisk oral amycretin study as completed, last updated March 5, 2025.↗

Status sources checked through July 22, 2026. See status sources and coverage →

What do the reviewed human studies say?

Human evidence reviewed September 15, 2026 · Review version 2.

Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.

Five selected reports cover early oral and subcutaneous amycretin studies, later phase 2 diabetes reports using the name zenagamtide, and a renal-function pharmacokinetic study. The two phase 2 reports describe separate route cohorts within one registered protocol.↗↗↗↗↗

What the reviewed sources report

Early trials reported weight reductions but were designed primarily to assess safety and tolerability. Later zenagamtide studies reported improved glycated hemoglobin in type 2 diabetes. Gastrointestinal adverse events and study discontinuations matter when interpreting these findings.↗↗↗↗

What remains unresolved?

  • How durable are effects after treatment ends, and what do longer studies show about serious harms?↗↗↗↗
  • How do results differ by formulation, population, attrition and the analysis of missing outcomes?↗↗↗↗

Read study designs, results, limitations, and sources →

Reviews summarize selected studies; their scope and limitations are shown above.

Research coverage and study families

Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.

Open machine-readable coverage and record decisions →

PubMed search

Primary reports of the named peptide administered in people, including pharmacology and secondary human-sample analyses. Reviews, modeling and preclinical reports remain indexed but are outside this human-administration subset.

24 retrieved · 5 included · 18 excluded · 1 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

"amycretin"[Title/Abstract] OR "zenagamtide"[Title/Abstract]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:57:48.291244+00:00 · HTTP 200 · SHA-256 fe0d181acf868f0104b711b5845cc6a3acb45e797c2c75a42a58ee55f28eefa8.

  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:57:49.699244+00:00 · HTTP 200 · SHA-256 1bc7520473a00be68abe188000c5a53f7a9ad13735f1bcdd361525402fe741e0.

  • Eligibility decisions use titles and abstracts from the pinned PubMed results; unavailable details remain unresolved rather than inferred.
  • Full-text appraisal, study-family reconciliation, registry history and broader alias/jurisdiction searches remain separate open work.

Showing 24 of 24 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. PubMed 42532080 — include: Original administered human study, including route-specific cohorts and renal pharmacokinetics; eligibility does not establish complete appraisal. Study families: NCT06542874.
  2. PubMed 42532079 — include: Original administered human study, including route-specific cohorts and renal pharmacokinetics; eligibility does not establish complete appraisal. Study families: NCT06542874.
  3. PubMed 42443140 — include: Original administered human study, including route-specific cohorts and renal pharmacokinetics; eligibility does not establish complete appraisal. Study families: NCT06559527.
  4. PubMed 40550231 — include: Original administered human study, including route-specific cohorts and renal pharmacokinetics; eligibility does not establish complete appraisal. Study families: NCT06064006.
  5. PubMed 40550229 — include: Original administered human study, including route-specific cohorts and renal pharmacokinetics; eligibility does not establish complete appraisal. Study families: NCT05369390.
  6. PubMed 40550232 — unresolved: No abstract in the retained record; the commentary-like title alone is insufficient for a definitive eligibility decision.
  7. PubMed 42673585 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
  8. PubMed 42568490 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
  9. PubMed 42452898 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
  10. PubMed 42444567 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
  11. PubMed 42315994 — exclude: Modular chemical assembly and cell assays, not a human amycretin administration study.
  12. PubMed 42208956 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
  13. PubMed 42175595 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
  14. PubMed 41948476 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
  15. PubMed 41850421 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
  16. PubMed 41747885 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
  17. PubMed 41344603 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
  18. PubMed 41255585 — exclude: Synthetic-data reconstruction and computational modeling of prior studies; no new participants receiving amycretin.
  19. PubMed 41054801 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
  20. PubMed 40949933 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
  21. PubMed 40706446 — exclude: Mice, rats and cell-based experiments, outside the human-administration subset.
  22. PubMed 40206909 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
  23. PubMed 40081498 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
  24. PubMed 39204092 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.

ClinicalTrials.gov search

ClinicalTrials.gov API v2 identity-name search, complete retrieved records. Includes protocols, extensions, combinations and expanded access; these are not all efficacy trials or published outcomes.

27 retrieved · 27 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

amycretin OR zenagamtide OR "NNC0487-0111" OR "NNC0487-0113"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:55:27.795004+00:00 · HTTP 200 · SHA-256 e78f79507abd0f48c62033a52bef89a4aef56de1b4dfdb91e9e7307623bf1b66.

  • Registry identity screening is distinct from appraisal of posted results, protocol history and publication linkage.
  • Other registries and unregistered studies are outside this search.

Showing 25 of 27 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. ClinicalTrials.gov NCT07757087 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07757087.
  2. ClinicalTrials.gov NCT06461039 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT06461039.
  3. ClinicalTrials.gov NCT07533175 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07533175.
  4. ClinicalTrials.gov NCT07815067 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07815067.
  5. ClinicalTrials.gov NCT06049329 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT06049329.
  6. ClinicalTrials.gov NCT07535307 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07535307.
  7. ClinicalTrials.gov NCT07668414 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07668414.
  8. ClinicalTrials.gov NCT07668401 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07668401.
  9. ClinicalTrials.gov NCT07508020 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07508020.
  10. ClinicalTrials.gov NCT07567001 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07567001.
  11. ClinicalTrials.gov NCT06064006 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT06064006.
  12. ClinicalTrials.gov NCT07797335 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07797335.
  13. ClinicalTrials.gov NCT06542874 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT06542874.
  14. ClinicalTrials.gov NCT07503210 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07503210.
  15. ClinicalTrials.gov NCT07339423 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07339423.
  16. ClinicalTrials.gov NCT05369390 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT05369390.
  17. ClinicalTrials.gov NCT06559527 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT06559527.
  18. ClinicalTrials.gov NCT07571109 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07571109.
  19. ClinicalTrials.gov NCT07121153 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07121153.
  20. ClinicalTrials.gov NCT07571005 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07571005.
  21. ClinicalTrials.gov NCT07509307 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07509307.
  22. ClinicalTrials.gov NCT07400107 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07400107.
  23. ClinicalTrials.gov NCT06820476 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT06820476.
  24. ClinicalTrials.gov NCT06478563 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT06478563.
  25. ClinicalTrials.gov NCT07720271 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07720271.

FDA search

Exact active-ingredient terms in the openFDA Drugs@FDA endpoint, checked September 15. A zero result describes this indexed query only, not worldwide nonapproval or every FDA document.

0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

products.active_ingredients.name:"AMYCRETIN" OR products.active_ingredients.name:"ZENAGAMTIDE" OR products.active_ingredients.name:"NNC0487-0111" OR products.active_ingredients.name:"NNC0487-0113"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:54:13.054316+00:00 · HTTP 404 · SHA-256 57b1e7534d003e4246182162fd2469cdf038de39405056f44fc006715e5496da.

  • This query does not cover all FDA safety communications, labels, compounding proceedings or other regulatory systems.

Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    EMA search

    Local identity matching in the pinned EMA medicines metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.

    0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

    Search terms, record decisions and remaining work

    Case-insensitive word-boundary matching of reviewed identity terms: ["amycretin", "zenagamtide", "NNC0487-0111", "NNC0487-0113"]

    Source retrievals and payload pins
    • Open the source endpoint ↗

      Retrieved 2026-09-15T08:34:22.905972+00:00 · HTTP 200 · SHA-256 a947c2b8a56ac2b92ec96156843f262f5e516f83b375d6791d67a8f6dc695729.

    • Complete source-document appraisal and national European sources remain open.
    • Zero identity matches apply only to these feed fields and terms.

    Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

      EMA search

      Local identity matching in the pinned EMA documents metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.

      0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

      Search terms, record decisions and remaining work

      Case-insensitive word-boundary matching of reviewed identity terms: ["amycretin", "zenagamtide", "NNC0487-0111", "NNC0487-0113"]

      Source retrievals and payload pins
      • Open the source endpoint ↗

        Retrieved 2026-09-15T08:34:29.167460+00:00 · HTTP 200 · SHA-256 c0c68d7d77783e0355cbc75bdd04772e9acc163236fc68abcd794477c4c3d439.

      • Complete source-document appraisal and national European sources remain open.
      • Zero identity matches apply only to these feed fields and terms.

      Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

        EMA search

        Local identity matching in the pinned EMA orphans metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.

        0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

        Search terms, record decisions and remaining work

        Case-insensitive word-boundary matching of reviewed identity terms: ["amycretin", "zenagamtide", "NNC0487-0111", "NNC0487-0113"]

        Source retrievals and payload pins
        • Open the source endpoint ↗

          Retrieved 2026-09-15T08:34:31.262344+00:00 · HTTP 200 · SHA-256 7448bf4e77e3345b3f3fbb7062c335d2302d8ea458a246bbe8256ce48aad2806.

        • Complete source-document appraisal and national European sources remain open.
        • Zero identity matches apply only to these feed fields and terms.

        Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

          Read the full Human Evidence Review

          Supervised synthesis

          What do selected human studies report about Amycretin?

          Manually reviewed September 15, 2026 · version 2

          Browse all Human Evidence Reviews · Open preserved synthesis version 2 →

          Five selected reports cover early oral and subcutaneous amycretin studies, later phase 2 diabetes reports using the name zenagamtide, and a renal-function pharmacokinetic study. The two phase 2 reports describe separate route cohorts within one registered protocol.12345

          Bottom line from this bounded source set

          Early trials reported weight reductions but were designed primarily to assess safety and tolerability. Later zenagamtide studies reported improved glycated hemoglobin in type 2 diabetes. Gastrointestinal adverse events and study discontinuations matter when interpreting these findings.1234

          Reviewed study record

          Oral amycretin: first-in-human study

          Design

          A blinded randomized placebo-controlled phase 1 study contained several escalating-exposure parts.1

          Population

          The study enrolled 144 adults with overweight or obesity across its parts.1

          Outcomes reported

          Treatment-emergent adverse events were reported in 89 participants and were mild or moderate; gastrointestinal events were common.1

          Limitations

          Safety was the primary endpoint; weight-related measures were exploratory. Small cohorts and short follow-up do not establish long-term clinical benefit or safety.1

          Reviewed study record

          Subcutaneous amycretin: phase 1b/2a study

          Design

          A randomized placebo-controlled multipart study assessed safety and secondary body-weight changes over up to 36 weeks.2

          Population

          The study randomized 125 adults with overweight or obesity at one research center.2

          Outcomes reported

          Estimated weight reductions were greater with amycretin. Gastrointestinal events were common, and the authors reported many study withdrawals.2

          Limitations

          Primary endpoints concerned adverse events. Small cohorts, different observation lengths and substantial attrition limit comparisons and interpretation of weight estimates.2

          Reviewed study record

          Oral zenagamtide: phase 2 diabetes cohort

          Design

          A blinded randomized placebo-controlled study assessed 36-week glycated hemoglobin change under NCT06542874.3

          Population

          This report included 186 adults with type 2 diabetes receiving metformin with or without an SGLT2 inhibitor.3

          Outcomes reported

          All three active groups improved glycated hemoglobin compared with placebo. Gastrointestinal events were common; seven participants in active groups had serious adverse events.3

          Limitations

          The primary analysis used on-treatment data without rescue medication. Glycemic improvement does not establish reduction in long-term complications; this cohort shares a protocol with the subcutaneous report.3

          Reviewed study record

          Subcutaneous zenagamtide: phase 2 diabetes cohort

          Design

          A blinded randomized placebo-controlled study assessed 36-week glycated hemoglobin change under NCT06542874.4

          Population

          This route cohort randomized 262 adults with type 2 diabetes; 261 received treatment.4

          Outcomes reported

          Active groups improved glycated hemoglobin compared with placebo. Gastrointestinal adverse events were common; serious adverse events were reported in active and placebo groups.4

          Limitations

          This is a route cohort within the same protocol as the oral report, not evidence from an unrelated replication. Follow-up and surrogate endpoints limit conclusions about long-term outcomes.4

          Reviewed study record

          Renal-function pharmacokinetic study

          Design

          A single-exposure study compared pharmacokinetics across renal-function groups with four weeks of follow-up, registered as NCT06559527.5

          Population

          Forty-two adults participated: 14 with normal renal function and seven each with mild, moderate or severe impairment or end-stage renal disease.5

          Outcomes reported

          The authors reported broadly comparable exposure measurements across groups. Treatment-emergent adverse events occurred in 30 of 42 participants; none were serious or severe, and most were mild gastrointestinal events.5

          Limitations

          Small groups, one exposure and short follow-up do not establish long-term safety or therapeutic benefit in people with kidney disease. The report does not support individualized treatment recommendations.5

          Reviewed source set

          1. PubMed · 40550229Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial. ↗PubMed PMID 40550229 · EFetch XML reviewed 2026-09-15 · payload SHA-256 54e5149216ac86bce906130f2c186b95c201d99d222e6af2f785c610e72e3137
            No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/s0140-6736(25)01176-6. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
          2. PubMed · 40550231Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. ↗PubMed PMID 40550231 · EFetch XML reviewed 2026-09-15 · payload SHA-256 e7375cc3b76d64492e736999fb294aa940d3a369b35d3e0f5fc7c59514bf5c80
            No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/s0140-6736(25)01185-7. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
          3. PubMed · 42532079Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. ↗PubMed PMID 42532079 · EFetch XML reviewed 2026-09-15 · payload SHA-256 a38bd67eb9127a41fddef95e4d6e879023591b667ddbfd8eb6531901dc42557b
            No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/s0140-6736(26)01247-x. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
          4. PubMed · 42532080Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. ↗PubMed PMID 42532080 · EFetch XML reviewed 2026-09-15 · payload SHA-256 bd2779fa1150d5ab1787f5a245e06368e1aa73edf5c6310f340e154d500e222e
            No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/s0140-6736(26)01248-1. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
          5. PubMed · 42443140Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide. ↗PubMed PMID 42443140 · EFetch XML reviewed 2026-09-15 · payload SHA-256 56ff4122a6898bfea6b5969ea65ecd7c4cef6fc282cb69818c791eaba39ba5c6
            No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1111/dom.71096. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
          Explore status sources, recent additions, and coverage gaps

          Living status brief

          What is the current status of Amycretin?

          Investigational. ClinicalTrials.gov lists a Novo Nordisk oral amycretin study as completed, last updated March 5, 2025.↗

          The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.

          3Dated records3PubMed records0Trial records0Regulatory records

          Evidence present

          What records are connected here?

          Evidence lanes
          1
          Source years
          1
          Drugs@FDA applications
          0

          These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

          Latest source-dated record

          What changed most recently at a cited source?

          Literature metadata · source date September 11, 2025

          PubMed record PMID 40550232↗Added to PeptideScanner August 10, 2026

          Coverage gaps

          What remains unknown or unsupported?

          PeptideScanner currently has no selected clinical trial records, regulatory records, and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

          PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

          Open the complete timeline →Browse all connected recordsFollow via RSS
          Explore the Evidence Map and record counts

          Evidence Map v1

          What kinds of records connect to Amycretin?

          Compare collection coverage →

          This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

          3Selected dated records
          4Connected citations
          1Populated source years2025
          1/4Record lanes present
          Clinical trials0No selected dated recordsLiterature metadata3Open matching records →Regulatory0No selected dated recordsSafety0No selected dated records

          Registered human studies

          Trial composition

          0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.

          PubMed bibliography

          Publication composition

          0 of 3 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

          Bibliography fields unavailable here for 3 selected records; the records remain visible as metadata observations.

          Regulatory and publication surfaces

          What is structurally connected?

          Drugs@FDA applications
          0
          FDA Federal Register documents
          0
          DailyMed SPL versions
          0
          Canonical profile
          Published
          Profile structured data
          Published
          Linked dated records
          3

          Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

          Profile publication history and record counts

          Research hub

          Explore the Amycretin evidence record

          Open all 3 records →
          3Dated records
          1Evidence type
          3Cited public sources
          1Source year

          Change ledger

          Recently changed for Amycretin

          Open all 4 events →

          PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

          Record added

          PubMed record PMID 40550229

          PeptideScanner retained PubMed bibliographic metadata for PMID 40550229 at 2026-07-30T18:25:48.707Z. PubMed recorded a metadata revision date of 2025-07-14 and an Entrez history date of 2025-06-23. PeptideScanner associated this retained record with the identity slug amycretin. These dates describe PubMed metadata history, not the article's original publication date.

          PeptideScanner change date
          August 10, 2026
          Cited source date
          July 14, 2025
          Evidence lane
          Literature metadata
          Open the cited record →
          Cited source
          Record added

          PubMed record PMID 40550231

          PeptideScanner retained PubMed bibliographic metadata for PMID 40550231 at 2026-07-30T18:25:48.707Z. PubMed recorded a metadata revision date of 2025-07-14 and an Entrez history date of 2025-06-23. PeptideScanner associated this retained record with the identity slug amycretin. These dates describe PubMed metadata history, not the article's original publication date.

          PeptideScanner change date
          August 10, 2026
          Cited source date
          July 14, 2025
          Evidence lane
          Literature metadata
          Open the cited record →
          Cited source
          Record added

          PubMed record PMID 40550232

          PeptideScanner retained PubMed bibliographic metadata for PMID 40550232 at 2026-07-30T18:22:52.359Z. PubMed recorded a metadata revision date of 2025-09-11 and an Entrez history date of 2025-06-23. PeptideScanner associated this retained record with the identity slug amycretin. These dates describe PubMed metadata history, not the article's original publication date.

          PeptideScanner change date
          August 10, 2026
          Cited source date
          September 11, 2025
          Evidence lane
          Literature metadata
          Open the cited record →
          Cited source

          Official-source collections

          Source records for Amycretin

          Open the full research atlas →

          Counts and links describe PeptideScanner’s selected records. They are not rankings and do not establish research quality, safety, effectiveness, or medical relevance.

          Evidence types

          Coverage by source year

          Selected records span July 14, 2025 to September 11, 2025.

          Continue exploring

          Profiles with overlapping source-year coverage

          Open the research atlas →

          These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

          Glucagon1 shared source year308 dated records · 4 evidence typesSemaglutide1 shared source year237 dated records · 4 evidence typesLeuprolide1 shared source year215 dated records · 4 evidence typesTirzepatide1 shared source year169 dated records · 4 evidence types

          These dates come from selected source records and PubMed metadata. They are not a complete or continuous timeline of research, safety, approval, or effectiveness.

          Evidence summary

          What the cited records say

          ClinicalTrials.gov lists a Novo Nordisk oral amycretin study as completed, last updated March 5, 2025.↗

          This is a source summary, not a medical recommendation. Status may differ by jurisdiction and product.

          Cited context

          Related records

          Organizations named in cited records

          • Novo Nordisk A/S↗

          Trial records

          Dated source history

          Updates connected to this profile

          Open the full cross-source timeline →

          1. Literature metadata

            PubMed record PMID 40550232↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 40550232 at 2026-07-30T18:22:52.359Z. PubMed recorded a metadata revision date of 2025-09-11 and an Entrez history date of 2025-06-23. PeptideScanner associated this retained record with the identity slug amycretin. These dates describe PubMed metadata history, not the article's original publication date.↗

          2. Literature metadata

            PubMed record PMID 40550229↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 40550229 at 2026-07-30T18:25:48.707Z. PubMed recorded a metadata revision date of 2025-07-14 and an Entrez history date of 2025-06-23. PeptideScanner associated this retained record with the identity slug amycretin. These dates describe PubMed metadata history, not the article's original publication date.↗

          3. Literature metadata

            PubMed record PMID 40550231↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 40550231 at 2026-07-30T18:25:48.707Z. PubMed recorded a metadata revision date of 2025-07-14 and an Entrez history date of 2025-06-23. PeptideScanner associated this retained record with the identity slug amycretin. These dates describe PubMed metadata history, not the article's original publication date.↗

          Public beta · Selective source coverageNot medical advice · No dosing or purchasing guidance